arrow
M

Michael W. Drazer

university of chicago
H指数:20
被引数:1,605

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Impact of Common Molecular Alterations and PD-L1 Expression on Overall Survival in a Select Cohort from the IASLC 9th Edition Staging Database

国际肺癌研究协会胸膜间皮瘤分期项目: 常见分子改变和PD-L1表达对IASLC第9版分期数据库选择队列总生存率的影响

2026-03-130
PRE
Outcomes of patients with relapsed/refractory acute leukaemia treated with revumenib with a focus on post-revumenib therapies

复发/难治性急性白血病接受revumenib治疗的患者结局,重点关注revumenib治疗后的疗法

2025-10-260
OAAI
Zeaxanthin augments CD8+ effector T cell function and immunotherapy efficacy

叶黄素增强CD8+效应T细胞功能及免疫治疗效果

2025-09-010
OAAI
Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults

成人TP53突变急性淋巴细胞白血病的临床与分子特征

2025-08-140
OAAI
Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma

多发性骨髓瘤患者接受及未接受来那度胺维持治疗时克隆性造血的演变

Leukemia
IF13.4
2025-07-160
OAAI
Predisposition to hematopoietic malignancies by deleterious germline CHEK2 variants

携带有害的胚系CHEK2变异导致的血液系统恶性肿瘤易感性

LEUKEMIA
IF13.4
2025-05-070
OA
Outcomes of BCR::ABL1-like B-Lineage Acute Lymphoblastic Leukemia in the Era of Novel Therapies

BCR::ABL1-like B系急性淋巴细胞白血病在新型疗法时代的结局

BLOOD
IF23.1
2024-11-050
PRE
Interim Results of a Phase II Study Investigating Dasatinib and Inotuzumab Ozogamicin-Based Induction for Newly-Diagnosed Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph plus ALL)

一项关于达沙替尼和伊诺妥单奥唑米星为基础诱导治疗新诊断费城染色体阳性急性淋巴细胞白血病(Ph plus ALL)的II期研究中期结果

BLOOD
IF23.1
2024-11-050
PRE
Targeting Menin in T-Lineage Acute Lymphoblastic Leukemia

靶向Menin在T系急性淋巴细胞白血病中的应用

BLOOD
IF23.1
2024-11-050
PRE
Intravenous Efgartigimod for the Treatment of Primary Immune Thrombocytopenia in Adults: A Planned, Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study with Open-Label Period (ADVANCE NEXT)

静脉注射Efgartigimod治疗成人原发性免疫性血小板减少症:一项计划中的III期、随机、双盲、安慰剂对照、平行分组研究(含开放标签期)(ADVANCE NEXT)

BLOOD
IF23.1
2024-11-050
PRE
Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms
2024-06-181
OAAI
Chronic Myeloid Leukemia, Version 2.2024

慢性粒细胞白血病2.2024版

2024-02-0116
OA